Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
General Outlook
In simple terms, Shanghai Henlius Biotech, Inc. has 543.495 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.737% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.182%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.216%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -0.078% return, is a testament to Shanghai Henlius Biotech, Inc.'s adeptness in optimizing resource deployment. Shanghai Henlius Biotech, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.354%. Furthermore, the proficiency of Shanghai Henlius Biotech, Inc. in capital utilization is underscored by a remarkable -0.150% return on capital employed.
Stock Prices
Shanghai Henlius Biotech, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $13.12, while its low point bottomed out at $12.68. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai Henlius Biotech, Inc.'s stock market.
